Rheumatoid Arthritis. Tocilizumab; a promising biological

Abstract

Ra is a relatively common, systemic and chronic autoimmune disease that has a prevalence of 1% in the western world. Ra has a very complex pathology in which a lot of different cell types and cytokines are involved. Because there is no definitive cure for RA, the major goals of RA treatment are to relieve pain, preserve joint function and minimize the tocicity from medications. There is still a need for new drugs. For example, because of the fact that, there are still patients that don’t respond to one of the current therapies. One example of a recently developed biological for the treatment of RA is Tocilizumab. Tocilizumab is a IL-6 blocking agent that promises to have a great future.